• Explore /
  • Poster
  • / A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab.

A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab.

Abstract Poster

Authors

null

Anne M. Noonan

The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Columbus, OH

Anne M. Noonan , Maryam B. Lustberg , Patrick Schnell , John L. Hays , Ning Jin , Laith I. Abushahin , Pannaga G. Malalur , Sameek Roychowdhury , Rifat T. Elkhatib , Huizi Chen , Salwan Al Mutar , Alex Sparreboom , Shuiying Hu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Late and Long-Term Adverse Effects

Clinical Trial Registration Number

NCT04164069

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS12125)

DOI

10.1200/JCO.2020.38.15_suppl.TPS12125

Abstract #

TPS12125

Poster Bd #

413

Abstract Disclosures

Similar Posters

First Author: Kathrin Heinrich

First Author: Mark H. O'Hara

First Author: Sang Hoon Chun

Poster

2023 ASCO Gastrointestinal Cancers Symposium

A meta-analysis of bevacizumab’s cardiovascular risks in patients treated for colorectal cancer.

A meta-analysis of bevacizumab’s cardiovascular risks in patients treated for colorectal cancer.

First Author: Akshit Chitkara